In a recent study posted to the bioRxiv* pre-print server, researchers investigated allosteric binders of angiotensin-converting enzyme 2 (ACE2) that significantly inhibit severe acute respiratory ...
In this rapidly evolving setting, clinicians are weighing the alleged harm of continuing these medications in patients for whom ACE inhibitors and ARBs have known benefit against the harm to their ...
Continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers before non-cardiac surgery is linked ...
Nothing has helped advance Dr. Onuigbo’s cause as much as the ONTARGET findings (N Eng J Med. 2008:358:1547-1559).The study showed that a combination of telmisartan and ramipril reduces proteinuria to ...
STOCKHOLM, SE / ACCESS Newswire / September 30, 2025 /Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today ...
In a recent study published in the Trends in Pharmacological Sciences, researchers engineered a mutant angiotensin-converting enzyme 2 (ACE2) decoy that effectively protected human lung epithelia from ...
Japan’s MHLW grants orphan drug designation to Vicore Pharma’s buloxibutid to treat idiopathic pulmonary fibrosis: Stockholm Wednesday, October 1, 2025, 17:00 Hrs [IST] Vicore ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback